About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, August 1st, 2016

The QualityStocks
Daily Stock List


PEN, Inc. (PENC)

DreamTeamNetwork, SmallCapVoice, and Outcast Traders reported earlier on PEN, Inc. (PENC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

PEN, Inc. is an international leader in developing, commercializing, and marketing enhanced-performance products enabled by nanotechnology. PEN stands for Products Enabled by Nanotechnology.  The Company concentrates on innovative and advanced product solutions in safety, health, and sustainability. Products from its family of companies are for healthcare to homecare, homeland defense to food security, and transportation to recreation. OTCQB-listed, PEN is based in Miami, Florida.

PEN is the combination of Nanofilm, Ltd. and Applied Nanotech Holdings, Inc. These are two nanotechnology innovators. PEN formed to channel the potential of nanotechnology in real-world products for real-world users. With the combination of these two companies, PEN provides nano-layer coatings, nano-based cleaners, and nano-composite products.

Nanofilm was established in 1985 by Mr. Scott Rickert, Chief Executive Officer of PEN. Applied Nanotech Holdings is a worldwide leader in nanotechnology research and development (R&D). It has greater than 25 years in the industry and holds over 250 patents.

PEN, via its wholly-owned subsidiary Nanofilm, develops, manufactures and sells products based on nanotechnology. This includes its Ultra Clarity® brand eyeglass cleaner and Defog It™ brand defogging products. PEN’s Applied Nanotech subsidiary in Austin, Texas functions as the Design Center conducting R&D services for government and private customers and new product development for PEN focusing on inventive and advanced product solutions.
PEN is developing a new category of cleaning products intended to clean and fortify surfaces at the nanoscale-level. Its products will incorporate natural elements and sustainable chemistry to keep surfaces safe. PEN launched its HALO™ product. It sells its HALO product through its wholly-owned subsidiary, PEN Technology, LLC. This is its first-of-its-kind everyday surface care product, a natural mineral protector and fortifier, and a cleaner that works at the nanometer scale to help create a healthy surface.

PEN announced earlier this year plans to expand the Clarity® branded optical products business through introducing new product categories, pioneering new products, and through expanding distribution channels. The initiative is supported by an abundant portfolio of Clarity products. These include eyewear and Clarity® Advanced - a new product line for cleaning the screens of consumer electronics.

Recently, PEN announced that its subsidiary, Nanofilm, Ltd., entered into a distribution agreement with a regional grocery retailer. Starting this past June, customers can find Nanofilm's CLARITY™ AR eyeglass cleaner in 2-ounce liquid spray, 50-ml foamer, and 4-ounce gel formats and also CLARITY DEFOG IT™ kits in the Eyecare/Earcare aisle of up to 200 grocery stores in Pennsylvania, Ohio, West Virginia and Maryland.

PEN, Inc. (PENC), closed Monday's trading session at $2.75, even for the day, on 1,984 volume with 7 trades. The average volume for the last 60 days is 734 and the stock's 52-week low/high is $0.008/$5.00.

Citius Pharmaceuticals, Inc. (CTXR)

OTCMagic, MicroCapDaily, Winston Small Cap, Stock Commander, Elite Stock Alerts, Journal Transcript, PennyStockLocks.com, StockRockandRoll, PennyDoctor, Wallstreet Profiler, SmallCapGrowth, KingPennyStocks, StockRunway, and DreamTeamNetwork reported recently on Citius Pharmaceuticals, Inc. (CTXR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company listed on the OTC Markets Group’s OTCQB. Its commitment is to developing and commercializing adjunctive cancer care and critical care drug products. The Company’s emphasis is on anti-infectives, cancer care and innovative prescription products utilizing unique, patented or proprietary formulations of earlier approved active pharmaceutical ingredients. Citius Pharmaceuticals is based in Cranford, New Jersey.

Presently, the Company is advancing two proprietary product candidates, its Mino-Lok™ product and a hydrocortisone-lidocaine formulation. The Mino-Lok™ product is advancing to Phase 3 clinical studies. The Mino-Lok™ product is an antibiotic lock solution. It is employed to treat patients with catheter-related bloodstream infections (CRBSIs).

The Company is developing a proprietary topical formulation of hydrocortisone (3%) and lidocaine (5%) to provide anti-inflammatory and anesthetic relief to persons suffering from Grade I and II hemorrhoids. Citius has achieved positive results from a Phase 2a study for hydrocortisone-lidocaine formulation for Grade I and II hemorrhoids. Citius works to take advantage of the Food and Drug Administration’s (FDA’s) 505(b)(2) pathway for new drug approvals and bring products to market quicker and with less cost versus other FDA new drug approval pathways.

Citius Pharmaceuticals’ development and commercialization goals include identifying later stage drug candidates, which can undergo development within a 3-4-year time frame utilizing a 505(b)(2) pathway; and licensing the most relevant and advanced technologies to provide superior product characteristics and intellectual property (IP) protection for 10 years.

The Company’s development and commercialization goals also include centering on therapeutic areas that are highly influenced by key opinion leaders (KOLs) and drugs that are prescribed by a relatively small number of physicians; and also providing cost-effective therapies that would be endorsed by patients, providers, and payers.

Today, Citius Pharmaceuticals provided shareholders with an update pertaining to its recent more notable achievements. Citius recently announced a $3 Million equity investment from its Executive Chairman, Mr. Leonard Mazur. Moreover, the Company made major strides in the development and commercialization efforts of its Mino-Lok™ and Hydro-Lido – Citius’ two premier products.

In addition, Citius Pharmaceuticals completed a feasibility study of major academic sites regarding conducting phase 3 trials for its Mino-Lok™ product. It has identified sites that are interested in participation. Citius reported positive results from the Phase 2a trial of its hydrocortisone and lidocaine combination product in patients with Grade I and II hemorrhoids.

Citius Pharmaceuticals, Inc. (CTXR), closed Monday's trading session at $1.06, up 1.92%, on 381,496 volume with 540 trades. The average volume for the last 60 days is 11,953 and the stock's 52-week low/high is $0.70/$2.50.

Exeo Entertainment, Inc. (EXEO)

RedChip, PennyStocks24, and Information Solutions Group reported previously on Exeo Entertainment, Inc. (EXEO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Exeo Entertainment, Inc. develops, designs, acquires, licenses, manufactures, and distributes innovative products in the video gaming, music, and smart TV sectors. It markets its products under the Psyko®, Krankz™, and Zaaz™ brands. The Company’s shares trade on the OTC Bulletin Board. Exeo Entertainment is headquartered in Las Vegas, Nevada.

The Company’s corporate mission is to make it easier for users to access interactive content through making technology available via patent, copyright, and intellectual property (IP) protected products to end users and developers. This is while providing an above market return to shareholders.

Exeo Entertainment’s strategy is to manufacture – by way of in-house product development – products that serve an existing need in the interactive marketplace and are capable of selling a minimum of 10,000 units each month.

Its Exeo 'Krankz™' Wireless On-Ear Headphone has a retractable, folding design with a built-in microphone. It also has on-ear controls to adjust one’s listening experience, with noise cancellation. Regarding Gaming Headphones, the Company’s Psyko 5.1/7.1 surround sound headset gives a user positional awareness when gaming.

In late June, Exeo Entertainment announced it entered into an exclusive distribution agreement with COKeM International Ltd. to distribute the patented Psyko® 5.1 gaming headphones. Exeo Entertainment has given COKeM exclusive distribution for a 12-month period to service BestBuy, Wal-Mart, Target, GameStop, as well as Fry's. COKeM continues to increase its capabilities. COKeM provides full-service distribution, fulfillment and 3PL services for a broad spectrum of industries and across numerous product categories.

Mr. Scott Amaral, Exeo Entertainment’s Chief Executive Officer, stated, "This is a big step in the right direction. First and foremost we need to have our products available where people shop. We need to give the end user the ability to interact with and listen to our product. The audio quality is unsurpassed and the psykowave technology creates the truest 3D sound available in the market. Our headphones offer true, unprocessed, surround-sound that provides the immersive experience that gamers want… We lack awareness and retail distribution is the first step in correcting that."

Exeo Entertainment, Inc. (EXEO), closed Monday's trading session at $1.20, down 4.00%, on 731 volume with 6 trades. The average volume for the last 60 days is 1,728 and the stock's 52-week low/high is $0.12/$1.25.

Protalex, Inc. (PRTX)

Money Morning, StreetInsider, TopStockAnalysts, Zacks, and OTCPicks reported earlier on Protalex, Inc. (PRTX), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Protalex, Inc. is a clinical-stage biopharmaceutical company with its corporate headquarters in Florham Park, New Jersey. Its emphasis is on the development of a class of drugs for treating autoimmune and inflammatory diseases. These include RA (Rheumatoid Arthritis) and ITP (Immune Thrombocytopenia). The Company’s lead product is PRTX-100. This is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. Protalex lists on the OTCQB.

Immune Thrombocytopenia (ITP) is a blood disorder. ITP can result in easy or excessive bleeding and bruising because of the body’s inability to form blood clots. Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP through lessening the immune-mediated destruction of the platelets.

Rheumatoid arthritis (RA) is an autoimmune disease. RA is a disorder in which the body’s immune system mistakenly attacks the joints. This results in painful inflammation in the joint area and deformation.

In the U.S., Protalex has open IND’s for the treatment of RA and ITP, and in Europe, an open IMPD for ITP. Its PRTX-100 has the ability (at very low concentrations) to bind to human B-lymphocytes and macrophages and to modulate immune processes. PRTX-100 has been granted Orphan Drug Designation in the U.S. and in Europe for the treatment of ITP. Currently, it is the subject of clinical studies in the U.S. and Europe.

Protalex announced this past May that following a planned interim data review by its independent Safety Monitoring Committee (SMC), it is continuing enrollment and increasing the dose for subjects in its European Phase 1b study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-203 Study). The dose of PRTX-100 for subjects in the next treatment group (6.0 micrograms/kg) will be twice that of the initial starting dosage (3.0 micrograms/kg). The 203 Study is an open-label, dose escalating study, which can enroll up to 30 patients in as many as five cohorts.

The safety, tolerability and pharmacokinetics of PRTX-100 have been characterized in six clinical studies. In three Phase 1b clinical trials in adult patients with active RA, PRTX-100 was generally safe and well tolerated at all dose levels. Moreover, at certain higher doses, more patients showed improvement in measures of RA disease activity than did patients at the lower dose or placebo cohorts. PRTX-100 is administered as a short intravenous infusion.

Protalex, Inc. (PRTX), closed Monday's trading session at $2.85, down 1.72%, on 300 volume with 3 trades. The average volume for the last 60 days is 1,390 and the stock's 52-week low/high is $2.03/$5.84.

Q BioMed, Inc. (QBIO)

SeeThruEquityResearch and Stock News Now reported recently on Q BioMed, Inc. (QBIO), StockPicksNYC did earlier, and today we report on the Company, here at the QualityStocks Daily Newsletter.

Q BioMed, Inc. is a biotechnology/biomedical acceleration and development enterprise. Its devotion is to acquiring and providing strategic resources to ‘clinical stage’ and ‘near value inflection’ healthcare companies. The Company previously went by the name ISMO Tech Solutions, Inc. It changed its name to Q BioMed, Inc. in July 2015. Essentially, Q BioMed concentrates on licensing and acquiring biomedical assets across the healthcare continuum. Q BioMed is headquartered in New York, New York.

The Company’s mission is to license and acquire ground-breaking life sciences assets from academia or small private companies. Additionally, its mission is to provide the strategic resources needed. This includes financial capital, intellectual capital, business development and scientific advice to hasten an entity’s product development timelines to commercialize their drug candidates or bring them to the next level in terms of valuation inflection.

Q BioMed is focusing on clinical stage and unique products where the technical, regulatory, and commercial risks have been reduced or major valuation inflections are pending. It has many assets across a wide array of healthcare related products, companies and sectors. These assets will undergo development to provide returns through organic growth or out-licensing, sale, or be spun out into new public companies. Q BioMed has been conducting due diligence on a number of potential assets for other indications with the aim of expanding its pipeline and enhancing shareholder value.

Q BioMed is also developing an inventive molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of IOP (Intraocular Pressure) - one of the primary causes of glaucoma. This platform is innovative and first-in-class. Q BioMed, together with its partner, Mannin Research, Inc., is the only company targeting this mechanism of action.

Q BioMed entered into an agreement with Mannin Research in October 2015 to exclusively license, with an option to acquire, the platform technology assets of Mannin Research. Mannin is the developer of a new class of vascular therapeutics. Its principal emphasis is developing a first-in-class therapeutic eye-drop for glaucoma in adults and children, utilizing a research platform designed to help develop new drugs for that indication and cystic kidney disease, among other diseases. Its lead drug candidate is MAN-01. The design of MAN-01 is to treat abnormal vessels within the eye, therefore treating glaucoma at its root causes.

In June, Q BioMed reported on a new potential asset license/acquisition and an update on Man-01 development. It entered into a definitive agreement to exclusively license a Food and Drug Administration (FDA) approved drug from a private U.S. company centered on the development of generic pharmaceuticals. The drug is indicated for the treatment of pain associated with metastatic bone cancer.

Furthermore, Mannin's primary indication, MAN-01 for treatment of POAG has initiated pre-clinical lead candidate optimization of a small molecule for topical application. Lead candidate selection is moving ahead on-time and on-budget. Mannin is also continuing its emphasis on research and discovery on the biology of Tie2/TEK signaling and its relationship with Schlemm's Canal function and regulation of intra-ocular pressure.

Q BioMed, Inc. (QBIO), closed Monday's trading session at $3.02, up 21.29%, on 18,474 volume with 57 trades. The average volume for the last 60 days is 8,928 and the stock's 52-week low/high is $1.26/$11.00.


The QualityStocks
Company Corner


eXp World Holdings, Inc. (EXPI)

The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $2.80, up 37.25%, on 23,351 volume with 57 trades. The stock’s average daily volume over the past 60 days is 7,654, and its 52-week low/high is $0.51/$2.042.

eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.

Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.

Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.

Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer

eXp World Holdings, Inc. Company Blog

eXp World Holdings, Inc. News:

Russ Cofano Joins eXp World Holdings and eXp Realty

Rick Miller and Randall Miles Join eXp World Holdings Board of Directors

Pokemon GO's Popularity Not Surprising to eXp Realty

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0036, up 5.88%, on 13,231,692 volume with 76 trades. The stock’s average daily volume over the past 60 days is 2,828,767 and its 52-week low/high is $0.003/$0.212.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Issues Open Letter to Shareholders

Dominovas Energy Announces Plan to Restructure and Consolidate Outstanding Debt

Dominovas Energy Welcomes Project Finance Team

Monaker Group, Inc. (MKGI)

The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.60, up 2.36%, on 5,741 volume with 18 trades. The stock’s average daily volume over the past 60 days is 6,723, and its 52-week low/high is $1.10/$5.95.

Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.

NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.

Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.

Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.

In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.

With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.

Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer

Monaker Group, Inc. Company Blog

Monaker Group, Inc. News:

Monaker Group Files Annual Report on Form 10K for Fiscal 2016

Monaker Group Shareholder Update

MissionIR Exclusive Audio Interview With Monaker Group, Inc. (MKGI) Chief Executive Officer

Laguna Blends Inc. (LAGBF)

The QualityStocks Daily Newsletter would like to spotlight Laguna Blends Inc. (LAGBF). Today, Laguna Blends Inc. closed trading at $0.19924, up 0.12%, on 12,227 volume with 3 trades. The stock’s average daily volume over the past 60 days is 17,605, and its 52-week low/high is $0.069/$0.261.

Laguna Blends Inc. (LAGBF) is a network marketing company focused on the generation of sales through independent affiliates. Leveraging innovative tools and technologies, the company's affiliates are able to build international businesses from their own homes while effectively capitalizing on the performance of some of the world's most rapidly expanding, in-demand markets. To date, Laguna's primary focus has been on the hyper growing hemp food and beverage marketplace. As part of these efforts, the company introduced Caffe, a hemp-infused instant coffee product, and is preparing to launch Pro369, a water soluble hemp protein powder.

As a network marketing company, Laguna is strategically positioned to grow very quickly following its entry into the rapidly expanding hemp market space. In early March 2016, the company gave prospective shareholders a preview of this potential when it launched sales of its protein coffee beverage through 135 independent affiliates throughout the United States and Canada. In less than a week, Laguna's affiliate base grew by more than 100 percent to include 278 independent marketers, demonstrating the high levels of demand for functional beverage products across North America, as well as the considerable interest in the viable business opportunity Laguna presents to its affiliates.

Through the commercialization of Caffe and Pro369, Laguna is establishing a foothold in two high-demand global markets. According to reports from the Coffee Association of Canada (CAC), coffee is consumed by a larger proportion of adults than any other beverage, excluding water. In recent years, the emergence of energy drinks has slowed the coffee industry's performance, but the single cup serving market, of which Caffe is a part, has maintained steady growth, rising above 32 percent market share as of January 2014, according to Mintel Research. With a product in this space - as well as the global hemp industry, which was valued at nearly $500 million in 2012 by the Hemp Industries Association - Laguna's initial offerings position it strongly for sustainable growth.

With growth through its marketing network already underway, Laguna has turned its attention toward further expansion of its product line. In March 2016, the company signed a letter of intent with Robert Lamberton Consulting regarding the development of a "Limitless functional beverage brain health and memory coffee" product. Under the terms of this LOI, all hard costs associated with the development of the product will be billed to Robert Lamberton Consulting. The two parties are expected to enter into a formal research and development agreement outlining the details of this arrangement in the second quarter of 2016.

Laguna is the first network marketing Company to use exciting virtual 3D technology to enable affiliates to train, recruit and drive sales by utilizing a simple interactive platform. Laguna believes this technology is a game changer in the Direct Selling / Network Marketing Industry. Disclaimer

Laguna Blends Inc. Company Blog

Laguna Blends Inc. News:

Laguna Recaps Key Milestones, Drivers to Corporate Growth Strategy

Laguna Announces that the Clinical Trial Data of CBD Cannaceuticals Facial Serum Resulted in a 100% Overall Improvement of the Skin Appearance Within Two Weeks

Laguna Signs Letter of Intent to Acquire Distribution Rights of Swiss Made Cannaceuticals CBD Skin Care Line and License of Brand Name in an Exclusive Licence Agreement that Includes Clinical Trials and Existing Inventory

OurPet's Company (OPCO)

The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.8854, up 0.61%, on 500 volume with 2 trades. The stock’s average daily volume over the past 60 days is 4,666, and its 52-week low/high is $0.631/$1.06.

OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.

In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.

The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.

OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer

OurPet's Company Company Blog

OurPet's Company News:

OurPet's Company (OPCO) Has a New Natural Solution to Your Cat Litter Woes

OurPet's Company Now Licensing Polymer Bonded Pet Bowl Patent

OurPet's Company Sponsors 65th Annual BetterInvesting National Convention


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Penny Stock Prodigy





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251